Effects of Antibiotic Therapy in Primary Sclerosing Cholangitis with and without Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
- 17 July 2019
- journal article
- review article
- Published by Georg Thieme Verlag KG in Seminars in Liver Disease
- Vol. 39 (04), 432-441
- https://doi.org/10.1055/s-0039-1688501
Abstract
The authors conducted a systematic review and meta-analysis to assess the effect of antibiotic therapy in primary sclerosing cholangitis (PSC). Effect of antibiotic therapy on Mayo PSC Risk Score (MRS), serum alkaline phosphatase (ALP), total serum bilirubin (TSB), and adverse events (AEs) rates were calculated and expressed as standardized difference of means or proportions. Five studies including 124 PSC patients who received antibiotics were included. Overall, antibiotic treatment was associated with a statistically significant reduction in ALP, MRS, and TSB by 33.2, 36.1, and 28.8%, respectively. ALP reduction was greatest for vancomycin (65.6%, p < 0.002) and smallest with metronidazole (22.7%, p = 0.18). Overall, 8.9% (95% confidence interval: 3.9-13.9) of patients had AEs severe enough to discontinue antibiotic therapy. In PSC patients, antibiotic treatment results in a significant improvement in markers of cholestasis and MRS. Antibiotics, particularly vancomycin, may have a positive effect on PSC either via direct effects on the microbiome or via host-mediated mechanisms.Keywords
This publication has 32 references indexed in Scilit:
- Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and ManagementGastroenterology, 2013
- The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse populationBMC Gastroenterology, 2011
- Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitisDigestive and Liver Disease, 2011
- High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitisHepatology, 2009
- Methodology and Indications of H2‐Breath Testing in Gastrointestinal Diseases: the Rome Consensus ConferenceAlimentary Pharmacology & Therapeutics, 2009
- Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitisThe Esophagus, 2006
- Bile Salt Hydrolase Activity in ProbioticsApplied and Environmental Microbiology, 2006
- Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitationPain, 2005
- Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo-controlled trialHepatology, 2004
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002